Neil Moorcroft
Aventis Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Neil Moorcroft.
Bioorganic & Medicinal Chemistry Letters | 2003
Christopher Adams; David J. Aldous; Shelley Amendola; Paul Lindsay Rhône-Poulenc Rorer Ltd Bamborough; Colin Bright; Sarah J. Crowe; Paul Robert Eastwood; Garry Fenton; Martyn Foster; Trevor K.P. Harrison; Sue King; Justine Lai; Christopher Lawrence; Jean-Philippe Letallec; Clive McCarthy; Neil Moorcroft; Kenneth Page; Sudha Rao; Shazia Sadiq; Keith Smith; John E. Souness; Sukanthini Thurairatnam; Mark Vine; Barry Wyman
The utilization and impact of parallel synthesis on lead exploration around initial hit oxindole (1) are described. The emergent SAR, analogue design and functional impact will also be detailed.
Organic and Biomolecular Chemistry | 2004
Sébastien L. Parisel; Neil Moorcroft; Anny Jutand; David J. Aldous; King Kuok (Mimi) Hii
A new generation of PNP compounds bearing different diarylphosphine groups were prepared and used as ligands in palladium-catalysed Suzuki cross-coupling reactions. Rates of oxidative addition of iodobenzene to (PNP)Pd[0] complexes were measured using UV spectroscopy. Synergistic effects between the N- and P- substituents were identified and correlated in redox and catalytic chemistry.
Bioorganic & Medicinal Chemistry Letters | 2013
Andrew Giovanni; Joachim E. Roehr; Shannon Dwyer; Kent W. Neuenschwander; Anthony C. Scotese; Neil Moorcroft; Larry Davis; Zhongli Gao
A series of tetrahydroisoquinolines were designed, synthesized and evaluated as the first non-natural product type of compounds with dual D(1) receptor (D(1)R) agonism and D(2) receptor (D(2)R) antagonism properties for treatment of schizophrenia. The initial SAR of the series was explored. The lead in the series, 3g, exhibited high affinity and good potency. Compound 3g displayed 95% of D(1)R occupancy (10 mg/kg, sc) and 75% of D(2)R occupancy (10 mg/kg, sc) in the striatum of male CD-1 mice. The series exhibited unique pharmacology and merit as tool compounds for target validation and future optimizations.
Archive | 2005
Philip M. Weintraub; Paul Robert Eastwood; Shujaath Mehdi; David Stefany; Kwon Yon Musick; Neil Moorcroft; Sungtaek Lim; John Z. Jiang; Hartmut Rütten; Stefan Peukert; Uwe Schwahn
Archive | 2004
John Z. Jiang; Jack Roger Koehl; Shujaath Mehdi; Neil Moorcroft; Kwon Yon Musick; Philip M. Weintraub; Paul Robert Eastwood
Archive | 2004
Ping Ge; Raymond F. Horvath; Lu Yan Zhang; Yasuchika Yamaguchi; Bernd Kaiser; Xuechun Zhang; Suoming Zhang; He Zhao; Stanly John; Neil Moorcroft; Greg Shutske
Archive | 2004
Kevin J. Hodgetts; Stanly John; Neil Moorcroft; Greg Shutske; Bernd Kaiser; Yasuchika Yamaguchi; Ping Ge; Raymond F. Horvath
Synlett | 2001
David J. Aldous; Shelley Bower; Neil Moorcroft; Michael Todd
Archive | 2003
Taeyoung Yoon; Ping Ge; Stephane Delombaert; Raymond F. Horvath; Dario Doller; Jingqi Lu; Kevin J. Hodgetts; Lu Yan Zhang; Stanly John; Bernd Kaiser; Xuechun Zhang; Greg Shutske; Cunyu Zhang; Jim Darrow; Neil Moorcroft; Yasuchika Yamaguchi
Archive | 2008
Stanly John; Raymond F. Horvath; Yan Lu Zhang; Yasuchika Yamaguchi; Bernd Kaiser; Xuechun Zhang; Suoming Zhang; He Zhao; Neil Moorcroft; Greg Shutske; Ge Ping